RVNC News and Press, Revance Therapeutics Inc. From 07/14/22

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. C...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In what turned out to be a challenging first quarter, Baron Discovery Fund (the “Fund”) decreased 16.30% (I...

Revance Therapeutics, Inc. (RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conf...

Revance Therapeutics press release (NASDAQ:RVNC): Q1 GAAP EPS of -$0.94 beats by $0.02. Revenue of $25.26M (+89.9% Y/Y) beats by $1.39M. For further details see: Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M

- PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection for glabellar lines - First quarter total revenue up 89.9% to $25.3 million, with RHA® Collection revenue up 78.9% to $20.8 million; Aesthetic accounts across products and services totaled over 3,500 ...

Conference Call Scheduled for Tuesday, May 10, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter fin...

Revance Therapeutics (NASDAQ:RVNC) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the company's application for resubmission of its DaxibotulinumtoxinA injection to treat moderate to severe glabellar (frown) lines. Despite the news, RVNC stock -11.2% to $15 in after...

- PDUFA goal date set for September 8, 2022 Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Applicati...

- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including Revance’s first oral presentation of the ASPEN-1 Phase 3 clinical trial data, and one poster detailing the positive topline results from the ASPEN Open Label Study (OLS), which demonstrated lo...